Britain and America have signed a major commercial pact that will ensure no tariffs on British medicine exports being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that duties on these key exports will stay at nothing for a period of 36 months.
This agreement is in response to recent warnings to dramatically increase import taxes on branded drug products, with figures floated as high as double the cost.
"This arrangement with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Significance
Drugs are one of the UK's largest export categories to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal protects employment, boosts capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal involves several specific pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to increase total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, refunds were more than 20%.
Industry Background
The pact takes place against a ongoing tension between the sector and the UK government over spending levels and approval rates.
This friction were intensified by arguments that US customers were charged a premium for the identical medicines than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a proportion of its resources over the last ten years.
